NEWS
HEADSPACE LAUNCHES INSURANCE-COVERED THERAPY DIRECT TO CONSUMERS, UNLOCKING ACCESS FOR 90 MILLION AMERICANS
Headspace, the world’ s most accessible and comprehensive mental health platform, has announced the launch of Therapy by Headspace, its direct-to-consumer therapy service, bringing affordable, evidence-based care to over 90 million Americans across all 50 states. After a decade of providing therapy through employers and health plans, the company is now making that same care available to consumers nationwide.
Affordable, insurance-covered therapy: Most members pay US $ 0 – US $ 35 per session via Headspace’ s in-network partnerships with over 45 national and regional insurance plans, such as Cigna, UnitedHealthcare, Optum and Blue Cross Blue Shield. Over the coming months, the company plans to add additional in-network plans to its offering.
Personalised, evidence-based care: 1:1 video sessions with licensed therapists trained in treating conditions like anxiety, trauma, mood disorders and more using proven modalities like cognitive behavioural therapy, acceptance and commitment therapy, dialectical behaviour therapy, and other evidence-based interventions.
An ecosystem of support between sessions: New members receive three months of complimentary access to the full Headspace app, thousands of hours of meditations, sleep and stress exercises, and ongoing support from Ebb, an empathetic AI companion.
Ebb offers real-time emotional support, personalised conversation and content recommendations like meditations or breathing exercises from the Headspace library. Between therapy sessions, members can turn to Ebb for reflection and everyday support, creating a continuous ecosystem of care that extends beyond the therapy session.
Jenna Glover, PhD, Chief Clinical Officer, Headspace, said:“ Through hundreds of thousands of sessions delivered over the years, we’ ve learned that when people have continuous support reinforcing their therapy work. Through guided meditations, personalised exercises and an AI companion that understands their specific challenges – they maintain momentum between sessions and see lasting results faster.”
ROCHE ANNOUNCES NEW COLLABORATION WITH BROAD CLINICAL LABS TO ACCELERATE ADOPTION OF CUTTING-EDGE SBX SEQUENCING TECHNOLOGY
Roche has announced a strategic collaboration with
Broad Clinical Labs to develop and pilot groundbreaking applications using Roche’ s recently unveiled next-generation sequencing( NGS) Sequencing By Expansion( SBX) technology. This collaboration will focus on harnessing the power of the SBX technology to transform clinical genomics and biomedical discovery. It will also aim to establish the SBX technology as a routine offering for fast, scalable sequencing for Broad Clinical Lab’ s research community. component of clinical care in neonatal intensive care units( NICUs) – enabling precise, timely diagnoses and improved outcomes for infants with suspected genetic disorders.
“ The SBX technology was designed with both clinical impact and scientific discovery in mind, and offers the next-generation of fast, scalable sequencing solutions,” said Matt Sause, CEO of Roche Diagnostics.“ Collaborating with Broad Clinical Labs, a leader in clinical genomics and omics research, accelerates our ability to deliver on that promise and support better outcomes for patients through cuttingedge genomic technology.”
The first project will see Broad Clinical Labs using the SBX technology to advance research into trio-based whole genome sequencing of critically ill newborns and their biological parents. This programme aims to establish a future state where whole genome sequencing becomes a routine
www. intelligenthealth. tech 7